logo
  • Home
  • Technologies
    • Live Cell Encapsulation
    • Research & Development
    • Cancer
    • Diabetes
    • Cannabinoids
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
    • International Diabetes Consortium
  • Investor Relations
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact

All SEC Filings

Navigation Toggle Navigation
  • Overview
  • News / Events
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
Filter Filings:
Date Form Description Docs XBRL Pages
04/14/21 EFFECT Notice of Effectiveness 1
04/05/21 S-3 Registration statement for specified transactions by certain issuers
Related Documents
EX-4.1
EX-5.1
EX-5.2
EX-10.1
EX-23.1
59
03/12/21 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-3.2
EX-31.1
EX-31.2
EX-32.1
EX-32.2
35
12/11/20 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
39
10/16/20 8-K Current report filing
Related Documents
EX-10.1
5
09/11/20 10-Q Quarterly report pursuant to Section 13 or 15(d)
Related Documents
EX-10.1
EX-10.2
EX-31.1
EX-31.2
EX-32.1
EX-32.2
44
08/13/20 10-K Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-21.1
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
136
07/29/20 SC 13D/A Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities 7
07/29/20 NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT 2
05/06/20 SC 13D Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities 7
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...27
  • Next >>

Contact Us

PharmaCyte Biotech, Inc.
23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92653
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Successfully Completes 1 Year Stability Study April 1, 2021
  • PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for its Clinical Trial Product January 26, 2021